Celanese Corporation (CE) is Selling Another 19% of Nutrinova for $152 Million. Is Deleveraging Worth Reducing Its Stake to 11%?
Celanese (CE) is selling 19% of Nutrinova to Mitsui for $152M, reducing its stake to 11%. The sale, expected to close Q4, will help reduce debt and fund maturities, part of a $1B divestiture goal by 2027. The sold stake generated $4M in 2025 earnings, implying a 38x multiple.
How this was made

The 30-second read
Why it matters
The transaction improves liquidity and reduces leverage but cuts future earnings exposure.
Market read
A material divestiture that modestly improves Celanese's balance sheet while reducing its earnings upside.
What to watch
Potential upside from Nutrinova's future expansion is now limited to a small 11% stake.
Background
Celanese is pursuing a $1 billion divestiture program by 2027, with this sale adding to a prior $500 million Micromax divestiture.
Ticker impact
Celanese announced sale of an additional 19% stake in Nutrinova for $152 million, reducing its holding to 11%.
Modest upside as debt reduction may lift valuation, but reduced future earnings from Nutrinova could cap gains.
Debt paydown is a positive catalyst, but loss of earnings contribution offsets some benefit.
Market effects
The chemicals sector may see slight re‑rating as Celanese improves its leverage profile.
U.S. industrials could benefit from the demonstrated focus on balance‑sheet discipline.
Limited; primarily affects Celanese and its peers.
Counterpoint
The sale may signal a strategic retreat from growth opportunities in specialty ingredients.
Key entities
- CompanyCelanese Corporation
U.S. chemicals manufacturer (NYSE:CE).
- CompanyMitsui & Co., Ltd.
Japanese conglomerate acquiring the Nutrinova stake.

